Schizophrenia Proteomics: Biomarkers on the Path to Laboratory Medicine
Author Information
Author(s): Lakhan Shaheen Emmanuel
Primary Institution: Global Neuroscience Initiative Foundation, Los Angeles, CA, USA
Hypothesis
Can proteomic approaches identify biomarkers for schizophrenia that could lead to better diagnostic and therapeutic strategies?
Conclusion
Proteomic studies have the potential to uncover biomarkers for schizophrenia, but significant challenges remain in translating these findings into clinical practice.
Supporting Evidence
- Proteomics studies have primarily focused on cancer, with limited research on psychiatric disorders like schizophrenia.
- Current proteomic methods have not yet revealed a biomarker with diagnostic specificity for schizophrenia.
- Ethical considerations are crucial in the application of proteomic technologies in vulnerable populations.
Takeaway
Scientists are trying to find special proteins in people with schizophrenia that could help doctors diagnose and treat the illness better.
Methodology
The article reviews various proteomic techniques, including mass spectrometry and protein profiling, to identify potential biomarkers in schizophrenia.
Potential Biases
There are ethical concerns regarding the use of biomarkers in vulnerable populations and the potential for misuse in eugenics or employment discrimination.
Limitations
Current proteomic studies have not yet identified a definitive biomarker for schizophrenia, and many studies are limited by sample size and methodology.
Participant Demographics
Schizophrenia affects nearly 1% of the global population, with equal risks across genders, typically manifesting after puberty and before age 25.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website